The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2022

Filed:

Jun. 22, 2020
Applicants:

Macrogenics, Inc., Rockville, MD (US);

Duke University, Durham, NC (US);

Inventors:

Scott Koenig, Rockville, MD (US);

Leslie S. Johnson, Rockville, MD (US);

Chia-Ying Kao Lam, Foster City, CA (US);

Liqin Liu, Germantown, MD (US);

Jeffrey Lee Nordstrom, Olney, MD (US);

Barton F. Haynes, Durham, NC (US);

Guido Ferrari, Durham, NC (US);

Assignees:

MacroGenics, Inc., Rockville, MD (US);

Duke University, Durham, NC (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C07K 16/10 (2006.01); C07K 16/08 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/283 (2013.01); C07K 16/084 (2013.01); C07K 16/085 (2013.01); C07K 16/1027 (2013.01); C07K 16/1063 (2013.01); C07K 16/2809 (2013.01); C12N 5/0638 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C12N 2510/00 (2013.01); C12N 2710/16211 (2013.01); C12N 2710/20011 (2013.01); C12N 2740/16111 (2013.01); C12N 2760/18511 (2013.01);
Abstract

The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.


Find Patent Forward Citations

Loading…